Copeptin predicts coronary artery disease cardiovascular and total mortality

Heart

Volumn 102, Issue 2, 2016, Pages 127-132

  Tasevska, Irina ^a,b   Enhörning, Sofia ^a,b   Persson, Margaretha ^a,b   Nilsson, Peter M ^a,b   Melander, Olle ^a,b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

COPEPTIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; BIOLOGICAL MARKER; GLYCOPEPTIDE;

AGE; AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GENDER; HEART INFARCTION; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SMOKING; SYSTOLIC BLOOD PRESSURE; BLOOD; DIABETES MELLITUS, TYPE 2; METABOLISM; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; SWEDEN;

AGED; BIOMARKERS; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; FEMALE; GLYCOPEPTIDES; HUMANS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; SMOKING; SWEDEN;

EID: 84958981346     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2015-308183     Document Type: Article

References (30)

1. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009;119:e21-181.
2. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008;117:e25-146.
3. Action to Control Cardiovascular Risk in Diabetes Study G, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59.
4. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-26.
5. Lolait SJ, O'carroll A-M, Mcbride OW, et al. Cloning and characterization of a vasopressin V2 receptor and possible link to nephrogenic diabetes insipidus. Nature 1992;357:336-9.
6. Filep J, Rosenkranz B. Mechanism of vasopressin-induced platelet aggregation. Thromb Res 1987;45:7-15.
7. Ohlstein EH, Berkowitz BA. Human vascular vasopressin receptors: analysis with selective vasopressin receptor antagonists. J Pharmacol Exp Ther 1986;239:737-41.
8. Whitton PD, Rodrigues LM, Hems DA. Stimulation by vasopressin, angiotensin and oxytocin of gluconeogenesis in hepatocyte suspensions. Biochem J 1978;176:893-8.
9. Keppens S, De Wulf H. The nature of the hepatic receptors involved in vasopressin-induced glycogenolysis. Biochim Biophys Acta 1979;588:63-9.
10. Holmes CL, Landry DW, Granton JT. Science review: vasopressin and the cardiovascular system part 1-receptor physiology. Crit Care 2003;7:427-34.
11. Abu-Basha EA, Yibchok-Anun S, Hsu WH. Glucose dependency of arginine vasopressin-induced insulin and glucagon release from the perfused rat pancreas. Metabolism 2002;51:1184-90.
12. Enhorning S, Bankir L, Bouby N, et al. Copeptin, a marker of vasopressin, in abdominal obesity, diabetes and microalbuminuria: the prospective Malmo Diet and Cancer Study cardiovascular cohort. Int J Obes (Lond) 2013;37:598-603.
13. Enhorning S, Struck J, Wirfält E, et al. Plasma copeptin, a unifying factor behind the metabolic syndrome. J Clin Endocrinol Metab 2011;96:E1065-72.
14. Enhorning S, Wang TJ, Nilsson PM, et al. Plasma copeptin and the risk of diabetes mellitus. Circulation 2010;121:2102-8.
15. Morgenthaler NG, Struck J, Alonso C, et al. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 2006;52:112-19.
16. Abbasi A, Corpeleijn E, Meijer E, et al. Sex differences in the association between plasma copeptin and incident type 2 diabetes: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study. Diabetologia 2012;55:1963-70.
17. Enhorning S, Hedblad B, Nilsson PM, et al. Copeptin is an independent predictor of diabetic heart disease and death. Am Heart J 2015;169:549-56.e1.
18. Stehouwer CD, Henry RM, Ferreira I. Arterial stiffness in diabetes and the metabolic syndrome: a pathway to cardiovascular disease. Diabetologia 2008;51:527-39.
19. Defronzo RA, Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia 2010;53:1270-87.
20. Adhikari N, Basi DL, Carlson M, et al. Increase in GLUT1 in smooth muscle alters vascular contractility and increases inflammation in response to vascular injury. Arterioscler Thromb Vasc Biol 2011;31:86-94.
21. Sell DR, Monnier VM. Molecular basis of arterial stiffening: role of glycation-a mini-review. Gerontology 2012;58:227-37.
22. Bornfeldt KE, Tabas I. Insulin resistance, hyperglycemia, and atherosclerosis. Cell Metab 2011;14:575-85.
23. Death AK, Fisher EJ, Mcgrath KCY, et al. High glucose alters matrix metalloproteinase expression in two key vascular cells: potential impact on atherosclerosis in diabetes. Atherosclerosis 2003;168:263-9.
24. Lavrentyev EN, Estes AM, Malik KU. Mechanism of high glucose induced angiotensin II production in rat vascular smooth muscle cells. Circ Res 2007;101:455-64.
25. Tada H, Shiffman D, Smith JG, et al. Twelve-single nucleotide polymorphism genetic risk score identifies individuals at increased risk for future atrial fibrillation and stroke. Stroke 2014;45:2856-62.
26. Fenske W, Störk S, Blechschmidt A, et al. Copeptin in the differential diagnosis of hyponatremia. J Clin Endocrinol Metab 2009;94:123-9.
27. Ludvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the Swedish national inpatient register. BMC Public Health 2011;11:450.
28. Lagerqvist B, James SK, Stenestrand U, et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007;356:1009-19.
29. Saleem U, Khaleghi M, Morgenthaler NG, et al. Plasma carboxy-terminal provasopressin (copeptin):a novel marker of insulin resistance and metabolic syndrome. J Clin Endocrinol Metab 2009;94:2558-64.
30. Roussel R, Fezeu L, Bouby N, et al. Low water intake and risk for new-onset hyperglycemia. Diabetes Care 2011;34:2551-4.